{"id":924824,"date":"2026-01-07T08:45:41","date_gmt":"2026-01-07T13:45:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-charming-medical-ltd-nasdaq-mcta-should-contact-wolf-haldenstein-immediately-5\/"},"modified":"2026-01-07T08:45:41","modified_gmt":"2026-01-07T13:45:41","slug":"shareholders-who-lost-money-in-shares-charming-medical-ltd-nasdaq-mcta-should-contact-wolf-haldenstein-immediately-5","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-charming-medical-ltd-nasdaq-mcta-should-contact-wolf-haldenstein-immediately-5\/","title":{"rendered":"Shareholders who lost money in shares Charming Medical Ltd. (NASDAQ: MCTA) Should Contact Wolf Haldenstein Immediately"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Lead Plaintiff Deadline is February 17, 2026<\/b>\n <\/p>\n

\n NEW YORK<\/span>, Jan. 7, 2026<\/span> \/PRNewswire\/ — Wolf Haldenstein Adler Freeman & Herz LLP<\/a> reminds purchasers or acquirers Charming Medical Ltd. (NASDAQ: MCTA)<\/b> (“Charming”) that a federal securities class action has been filed on behalf of investors who purchased Charming between October 21, 2025 and\u00a0 November 12, 2025, inclusive (the “Class Period”). Investors have until February 17, 2026 to seek appointments as lead plaintiff.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Wolf
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n
\n PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION<\/a>
\n <\/b>\n <\/p>\n

The filed complaint alleges<\/span> violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. According to the lawsuit, Charming Medical’s stock price experienced a rapid and artificial surge following its Initial Public Offering (“IPO”) rising from $4.00 per share to a high of $29.36 without any corresponding fundamental company news.<\/p>\n

Plaintiffs allege<\/span> that this price increase was driven by a fraudulent, social-media-based stock promotion scheme. Investigations and public reporting revealed that impersonators posing as financial advisors promoted Charming Medical through online forums, chat groups, and social media, making sensational and unsupported claims designed to induce retail investor buying.<\/p>\n

In November 2025, trading in Charming Medical securities was suspended, allegedly<\/span> exposing the artificial nature of the run-up and causing investor losses.<\/p>\n

The proposed class consists of all persons and entities who purchased Charming Medical securities during the class period and were damaged as a result, excluding defendants and their affiliates.<\/p>\n

\n Lead Plaintiff Deadline:<\/b> Investors have until FEBRUARY 17, 2026 <\/b>to contact the firm<\/a> to discuss how to become a lead plaintiff.<\/p>\n

\n Why\u00a0<\/b>
\n
\n Wolf Haldenstein Adler Freeman & Herz LLP?<\/a>
\n <\/b>
\n :<\/b>\n <\/p>\n

This illustrious firm,<\/a> founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements.\u00a0The law firm\u00a0<\/a>brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.<\/p>\n

We encourage all investors who have been affected or have information that will assist in our investigation, to contact\u00a0Wolf Haldenstein Adler Freeman & Herz LLP.<\/a><\/p>\n

\n Contact:<\/b>\n <\/p>\n